Author: Xia, Shuai; Yan, Lei; Xu, Wei; Agrawal, Anurodh Shankar; Algaissi, Abdullah; Tseng, Chien-Te K.; Wang, Qian; Du, Lanying; Tan, Wenjie; Wilson, Ian A.; Jiang, Shibo; Yang, Bei; Lu, Lu
Title: A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike Document date: 2019_4_10
ID: 3c5ab73l_62
Snippet: Briefly, mice expressing human DPP4 were randomly separated into three groups (n = 6): viral control, prophylactic group, and therapeutic group. In the viral control and therapeutic groups, each mouse was challenged intranasally with 10 4 TCID 50 [i.e., 1000 LD 50 (median lethal dose)] of MERS-CoV in a volume of 60 ïl, 30 min after viral challenge, and then treated via the intranasal route with 200 ïg of EK1 (in 50 ïl of PBS) or 50 ïl of .....
Document: Briefly, mice expressing human DPP4 were randomly separated into three groups (n = 6): viral control, prophylactic group, and therapeutic group. In the viral control and therapeutic groups, each mouse was challenged intranasally with 10 4 TCID 50 [i.e., 1000 LD 50 (median lethal dose)] of MERS-CoV in a volume of 60 ïl, 30 min after viral challenge, and then treated via the intranasal route with 200 ïg of EK1 (in 50 ïl of PBS) or 50 ïl of PBS, respectively. Prophylactic group mice were pretreated via the intranasal route with 200 ïg of EK1 per mouse 30 min before viral challenge. Challenged mice were monitored daily for weight loss and mortality. In the interim, two mice were randomly euthanized (two of six) in each group at day 2 after challenge to determine the lung virus titers by CPE on Vero E6 and expressed as TCID 50 /ml.
Search related documents:
Co phrase search for related documents- intranasal route and prophylactic group: 1, 2
- intranasal route and viral challenge: 1, 2
- intranasally challenge and lung virus: 1
- intranasally challenge and viral challenge: 1, 2, 3
- intranasally challenge and viral control: 1, 2
- intranasally challenge and weight loss: 1, 2, 3
- lung virus and mortality weight loss: 1, 2
- lung virus and viral challenge: 1, 2, 3, 4, 5, 6, 7, 8, 9
- lung virus and viral control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- lung virus and weight loss: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- lung virus titer and viral challenge: 1
- lung virus titer and weight loss: 1, 2, 3, 4, 5
- mortality weight loss and viral challenge: 1
- mortality weight loss and weight loss: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- prophylactic group and therapeutic group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- prophylactic group and therapeutic group prophylactic group: 1, 2, 3, 4
- therapeutic group and viral control: 1
- viral challenge and weight loss: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- viral control and weight loss: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date